Business Context and Reporting Period
This Form 8-K filing by Abbott Laboratories reports on events occurring on April 28, 2017, specifically the company's Annual Meeting of Shareholders and a concurrent amendment to its by-laws. The filing serves as a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Key Financial Metrics
This filing is a corporate governance report and does not contain financial performance data. There are no disclosures regarding revenue, profit, cash flow, margins, debt, or liquidity in this document.
Material Changes and Governance Actions
- Board Size Reduction: The Board of Directors amended the by-laws to reduce the number of directors from twelve to eleven, effective April 28, 2017.
- Director Elections: Shareholders elected the entire Board of Directors. All nominees received majority support, though vote counts varied by individual.
- Auditor Ratification: Shareholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm.
- Executive Compensation: Shareholders approved the advisory "say-on-pay" proposal with 94.78% support.
- Compensation Frequency: Shareholders voted to approve annual "say-on-pay" votes (89.43% support).
- Stock Plans: The 2017 Incentive Stock Program (88.66% support) and the 2017 Employee Stock Purchase Plan for Non-U.S. Employees (98.27% support) were approved.
- Shareholder Proposal Rejection: A proposal to require an independent Board Chairman was rejected, receiving only 37.06% of the votes cast.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, or specific risk factors. The document is limited to reporting the outcomes of shareholder votes and the by-law amendment.
Key Facts for Investor Verification
- Verify the effective date of the by-law amendment reducing the Board size to eleven members.
- Confirm the specific vote counts for the rejected shareholder proposal regarding an independent Board Chairman.
- Review the approved 2017 Incentive Stock Program and Employee Stock Purchase Plan details for potential dilution impacts.
- Note that this filing contains no financial results; refer to the most recent 10-Q or 10-K for financial performance data.